Matthias Puls took over as CereGate's chief executive just over a year ago. The Munich company had spent six years building a therapy that adds no new implant to a Parkinson's patient's head. The hardware is already there: a Boston Scientific deep brain stimulation generator seated in the subthalamic nucleus. CereGate's software adds a second programme to the clinical workflow, bursts of stimulation timed as a walking cue. The patient switches it on when a step will not start.
On 14 October, CereGate said it had closed an oversubscribed Series C. The amount was not disclosed. Neither was the valuation, the ownership split, or the name of the lead investor, described only as "a global US-based medtech company." Impact Ventures of Budapest joined as a new backer. Existing investors followed: 468 Capital, re.Mind Capital, Heal Capital, HTGF, TruVenturo.
The missing number is the interesting part. A strategic medtech lead financing a software layer that runs on implants already in patients is making a distribution bet. If that lead builds deep brain stimulation systems itself, the round ties a hardware maker to a therapy that expands what its installed base can do. Inside BCI raised exactly that question and did not get an answer.
Puls framed the money around clinical work. The round, he said, lets CereGate "take our therapy through the clinical work that matters most, in an indication where few options remain once medication and standard stimulation stop working."
The cue, not the implant
Freezing of gait is a specific failure. A Parkinson's patient is walking, then stops, unable to restart despite intending to move. Deep brain stimulation can control the symptoms that respond to dopamine and still leave this gap. CereGate's own release says freezing responds poorly to established forms of stimulation. That admission is the whole business case, because it means the installed base of implants is not finished working.
CereGate describes the cue as the same idea as the rhythmic sounds and visual markers used in Parkinson's rehabilitation, moved inside the body. Its claim is that the signal can travel through the implant instead. A timed bursting pattern is a different intervention, delivered by the same generator.
The commercial logic follows the clinical one. Boston Scientific has already sold the generators. A software programme that improves walking on those generators reaches patients without another surgery, another hardware approval cycle, or a new implant to manufacture. The constraint sits in the clinic, not the factory: someone has to tune the pattern for each patient.